News - Acura Pharmaceuticals Inc.
BRISTOL, Tenn. and PALATINE, Ill., Dec. 20, 2010 /PRNewswire-FirstCall/ -- King Pharmaceuticals®, Inc. (NYSE: KG) and Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) today announced that King has submitted a New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets to the U.S.
PALATINE, Ill. and BRISTOL, Tenn., April 22 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals®, Inc. (NYSE: KG) today announced that the U.S.
PALATINE, Ill. and BRISTOL, Tenn., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S.
PALATINE, Ill. and BRISTOL, Tenn., June 17, 2008 (PRIME NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) and King Pharmaceuticals, Inc. (NYSE:KG) today announced positive top-line results from Acura's pivotal Phase III study, AP-ADF-105 ("Study 105").